Entera Bio Ltd. reported on February 4, 2026, that Gerald Ostrov resigned from its Board of Directors on January 29, 2026, with Steven D. Rubin being appointed as a director, effective February 1, 2026. Additionally, the company has expanded its collaboration agreement with OPKO Health to develop a long-acting PTH tablet for treating hypoparathyroidism, sharing development costs equally.